These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36792677)

  • 1. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs.
    Sotillo S; Ward JL; Guillot E; Domenig O; Yuan L; Smith JS; Gabriel V; Iennarella-Servantez CA; Mochel JP
    Sci Rep; 2023 Feb; 13(1):2684. PubMed ID: 36792677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
    Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
    Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs.
    Mochel JP; Peyrou M; Fink M; Strehlau G; Mohamed R; Giraudel JM; Ploeger B; Danhof M
    J Vet Pharmacol Ther; 2013 Apr; 36(2):174-80. PubMed ID: 22568394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
    Lantis AC; Ames MK; Atkins CE; DeFrancesco TC; Keene BW; Werre SR
    J Vet Pharmacol Ther; 2015 Feb; 38(1):65-73. PubMed ID: 25224804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs.
    Adin D; Atkins C; Wallace G; Klein A
    J Vet Intern Med; 2021 May; 35(3):1245-1254. PubMed ID: 33713485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs.
    Masters AK; Ward JL; Guillot E; Domenig O; Yuan L; Mochel JP
    PLoS One; 2024; 19(2):e0298030. PubMed ID: 38394253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
    Lantis AC; Ames MK; Werre S; Atkins CE
    J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
    Schneider BK; Ward J; Sotillo S; Garelli-Paar C; Guillot E; Prikazsky M; Mochel JP
    Sci Rep; 2023 Feb; 13(1):3300. PubMed ID: 36843132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
    Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
    Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN; Mauron C; Kaiser G
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism.
    Adin D; Atkins C; Domenig O; DeFrancesco T; Keene B; Tou S; Stern JA; Meurs KM
    J Vet Intern Med; 2020 Mar; 34(2):600-606. PubMed ID: 32112596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned?
    Mochel JP; Danhof M
    Rev Physiol Biochem Pharmacol; 2015; 169():43-69. PubMed ID: 26428686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
    Ames MK; Atkins CE; Lantis AC; zum Brunnen J
    J Renin Angiotensin Aldosterone Syst; 2016; 17(1):1470320316633897. PubMed ID: 27009288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
    Mentz RJ; Stevens SR; DeVore AD; Lala A; Vader JM; AbouEzzeddine OF; Khazanie P; Redfield MM; Stevenson LW; O'Connor CM; Goldsmith SR; Bart BA; Anstrom KJ; Hernandez AF; Braunwald E; Felker GM
    JACC Heart Fail; 2015 Feb; 3(2):97-107. PubMed ID: 25543972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amlodipine on the circulating renin-angiotensin-aldosterone system in healthy cats.
    Garcia Marrero TM; Ward JL; Tropf MA; Bourgois-Mochel A; Guillot E; Domenig O; Yuan L; Kundu D; Mochel JP
    J Vet Intern Med; 2024; 38(2):913-921. PubMed ID: 38334012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
    King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
    Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
    Kitagawa H; Eguchi T; Kitoh K; Ohba Y; Kondo M; Nakano M; Sasaki Y
    J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.